ANI Pharmaceuticals (ANIP) News Today → What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (From Weiss Ratings) (Ad) Free ANIP Stock Alerts $64.90 +1.44 (+2.27%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 11:37 AM | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Large Decrease in Short InterestANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 204,400 shares, a decline of 11.1% from the April 30th total of 229,900 shares. Based on an average daily trading volume, of 159,600 shares, the days-to-cover ratio is currently 1.3 days.June 1 at 1:24 AM | americanbankingnews.comBrokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $81.00May 29, 2024 | globenewswire.comANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare ConferenceMay 29, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Buy" from AnalystsShares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have earned an average recommendation of "Buy" from the four brokerages that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation. The average 1-year price obMay 28, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Trexquant Investment LPTrexquant Investment LP decreased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 34.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,484 shares of the speciMay 23, 2024 | insidertrades.comChristopher Mutz Sells 2,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockMay 22, 2024 | marketbeat.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Insider Sells 2,000 Shares of StockANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) insider Christopher Mutz sold 2,000 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $61.61, for a total value of $123,220.00. Following the completion of the sale, the insider now directly owns 83,277 shares in the company, valued at approximately $5,130,695.97. The transaction was disclosed in a document filed with the SEC, which is available through this link.May 22, 2024 | insidertrades.comMuthusamy Shanmugam Sells 12,855 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockMay 21, 2024 | marketbeat.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells 12,855 Shares of StockANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) COO Muthusamy Shanmugam sold 12,855 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $61.81, for a total transaction of $794,567.55. Following the transaction, the chief operating officer now owns 732,620 shares in the company, valued at $45,283,242.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.May 21, 2024 | marketbeat.comGlobal Alpha Capital Management Ltd. Increases Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Global Alpha Capital Management Ltd. boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 10.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 582,428 shares of the specialty pharmaceutical company's stock after acquiring an additionMay 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)May 20, 2024 | markets.businessinsider.comANI Pharma Launches Kionex Suspension For Oral Or Rectal UseMay 20, 2024 | globenewswire.comANI Pharmaceuticals Announces the Launch of Kionex® SuspensionMay 18, 2024 | finance.yahoo.comDirector Renee Tannenbaum Sells 2,000 Shares of ANI Pharmaceuticals Inc (ANIP)May 18, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Renee P. Tannenbaum Sells 2,000 SharesMay 17, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Sells $1,101,820.90 in StockMay 16, 2024 | finance.yahoo.comInsider Selling: President & CEO Nikhil Lalwani Sells Shares of ANI Pharmaceuticals Inc (ANIP)May 16, 2024 | marketbeat.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Sells 16,669 Shares of StockANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CEO Nikhil Lalwani sold 16,669 shares of the company's stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $66.10, for a total value of $1,101,820.90. Following the transaction, the chief executive officer now owns 377,505 shares of the company's stock, valued at $24,953,080.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.May 14, 2024 | insidertrades.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 250 Shares of StockMay 13, 2024 | marketbeat.comMeredith Cook Sells 250 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 250 shares of the company's stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $67.69, for a total transaction of $16,922.50. Following the transaction, the vice president now owns 59,481 shares of the company's stock, valued at $4,026,268.89. The transaction was disclosed in a filing with the SEC, which is available through this link.May 13, 2024 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) PT Raised to $87.00HC Wainwright boosted their price target on ANI Pharmaceuticals from $83.00 to $87.00 and gave the stock a "buy" rating in a research report on Monday.May 13, 2024 | finance.yahoo.comANI Pharmaceuticals Inc (ANIP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...May 13, 2024 | finance.yahoo.comANI Pharmaceuticals, Inc. Just Beat EPS By 459%: Here's What Analysts Think Will Happen NextMay 12, 2024 | marketbeat.comThompson Siegel & Walmsley LLC Sells 15,796 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Thompson Siegel & Walmsley LLC decreased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 6.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 212,911 shares of the sMay 11, 2024 | finance.yahoo.comANI Pharmaceuticals First Quarter 2024 Earnings: Beats ExpectationsMay 11, 2024 | finance.yahoo.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comANI Pharmaceuticals Reports Strong Q1 2024 Results, Surpassing Revenue ExpectationsMay 10, 2024 | finanznachrichten.deANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 GuidanceMay 10, 2024 | sfgate.comANI: Q1 Earnings SnapshotMay 10, 2024 | markets.businessinsider.comANI Pharmaceuticals, Inc. Q1 Profit Increases, Beats EstimatesMay 10, 2024 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Updates FY24 Earnings GuidanceANI Pharmaceuticals (NASDAQ:ANIP) updated its FY24 earnings guidance. The company provided EPS guidance of $4.26-4.67 for the period, compared to the consensus estimate of $4.48. The company also issued revenue guidance of $520-542 millionillion, compared to the consensus estimate of $535.14 millionillion.May 10, 2024 | globenewswire.comANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 GuidanceMay 9, 2024 | finance.yahoo.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies AheadMay 9, 2024 | finance.yahoo.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?May 5, 2024 | marketbeat.comSummit Global Investments Invests $773,000 in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Summit Global Investments bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,027 shares of the specialty pharmaceutiMay 5, 2024 | insidertrades.comChad Gassert Sells 20,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockMay 4, 2024 | insidertrades.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells 20,000 Shares of StockMay 3, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells $1,332,400.00 in StockANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Chad Gassert sold 20,000 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $66.62, for a total value of $1,332,400.00. Following the completion of the sale, the senior vice president now directly owns 233,226 shares of the company's stock, valued at $15,537,516.12. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.May 1, 2024 | globenewswire.comANI Pharmaceuticals to Participate at Two Upcoming Healthcare ConferencesApril 30, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Large Increase in Short InterestANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 213,500 shares, a growth of 8.4% from the March 31st total of 197,000 shares. Based on an average daily trading volume, of 142,800 shares, the short-interest ratio is presently 1.5 days.April 27, 2024 | seekingalpha.comANIP ANI Pharmaceuticals, Inc.April 23, 2024 | markets.businessinsider.comEvaluating ANI Pharmaceuticals: Insights From 5 Financial AnalystsApril 23, 2024 | marketbeat.comGuggenheim Reaffirms Buy Rating for ANI Pharmaceuticals (NASDAQ:ANIP)Guggenheim restated a "buy" rating and set a $77.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday.April 23, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells $1,095,442.53 in StockApril 22, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 16,809 SharesANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) COO Muthusamy Shanmugam sold 16,809 shares of the firm's stock in a transaction on Friday, April 19th. The shares were sold at an average price of $65.17, for a total transaction of $1,095,442.53. Following the completion of the transaction, the chief operating officer now directly owns 782,620 shares of the company's stock, valued at $51,003,345.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.April 19, 2024 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2024 Earnings GuidanceANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2024 earnings guidance. The company provided EPS guidance of 4.260-4.670 for the period, compared to the consensus estimate of 4.470. The company also issued revenue guidance of $520.0 millionillion-$542.0 millionillion, compared to the consensus estimate of $534.2 millionillion.April 19, 2024 | investing.comAni Pharmaceuticals executive sells over $1.5 million in company stockApril 18, 2024 | globenewswire.comANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ETApril 18, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 7,414 SharesApril 16, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $16,947.50 in Stock Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. ANIP Media Mentions By Week ANIP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIP News Sentiment▼1.110.76▲Average Medical News Sentiment ANIP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIP Articles This Week▼74▲ANIP Articles Average Week Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Catalyst Pharmaceuticals News CytomX Therapeutics News DURECT News RedHill Biopharma News Cytokinetics News Apellis Pharmaceuticals News Madrigal Pharmaceuticals News Alpine Immune Sciences News Nuvalent News Alkermes News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIP) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
